To validate hyperactivation of those pathways with therapy resistance, the genes KDR, FGFR3, AKT3, JAK2, STAT3 were selected because they are frequently amplified in bladder cancer [45]. This evidence concerns the gene JAK2 and urinary bladder cancer.